ConductScience.org, home

Comparison · NCT01727336-7b574b9b

Part 2: Dalantercept 0.9 mg/kg Plus Axitinib vs Part 2: Placebo Plus Axitinib: Part 2: Disease Control Rate.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Part 2: Dalantercept 0.9 mg/kg Plus Axitinib vs Part 2: Placebo Plus Axitinib: Part 2: Disease Control Rate. Trial comparisons, record NCT01727336-7b574b9b. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01727336-7b574b9b

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.8280.7110.904wilson
Risk in group 20.820.7050.896wilson
Risk difference, group 1 minus group 20.00791-0.1320.145newcombe hybrid score
Risk ratio, group 1 over group 21.010.8551.19log
Odds ratio, group 1 over group 21.060.4112.71log
Number needed to treat, for one more participant with the outcome on Part 2: Dalantercept 0.9 mg/kg Plus Axitinib than on Part 2: Placebo Plus Axitinib126from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Part 2: Dalantercept 0.9 mg/kg Plus AxitinibSubcutaneous (SC) injection of Dalantercept 0.9 mg/kg once every 3 weeks and oral axitinib 5 mg BID for continuous dosing.4858OG000
Group 2Part 2: Placebo Plus AxitinibSubcutaneous injection of normal saline once every 3 weeks and oral axitinib 5 mg BID for continuous dosing5061OG001

Outcome

Type
SECONDARY
Title
Part 2: Disease Control Rate.
Description
The number and percentage of patients whose disease shrinks or remains stable. DCR is the sum of the complete, partial and stable disease rates.
Time frame
Assessed at 30 days after last dose of study drug. The time frame for Part 2 was up to 29.0 months
Population
The All Treated Set (ATS) included all randomized patients who received any study drug

Source ClinicalTrials.gov

Trial

Title
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
NCT number
NCT01727336
Phases
PHASE2
Conditions
Advanced Renal Cell Carcinoma
Interventions
Dalantercept and axitinib, Placebo and axitinib
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Results first posted
2021-05-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01727336-7b574b9b